238120 — Aligned Genetics Balance Sheet
0.000.00%
- KR₩45bn
- KR₩31bn
- KR₩16bn
- 74
- 59
- 64
- 77
Annual balance sheet for Aligned Genetics, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 12,139 | 13,137 | 13,696 | 14,927 | 18,019 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 1,519 | 2,563 | 1,469 | 2,723 | 2,951 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 15,942 | 18,386 | 19,552 | 21,603 | 25,567 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1,673 | 5,776 | 7,285 | 8,035 | 7,770 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 25,481 | 34,469 | 36,901 | 40,932 | 44,275 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1,219 | 1,417 | 1,333 | 5,238 | 1,896 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 4,017 | 7,477 | 8,052 | 9,620 | 8,781 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 21,464 | 26,992 | 28,850 | 31,311 | 35,494 |
| Total Liabilities & Shareholders' Equity | 25,481 | 34,469 | 36,901 | 40,932 | 44,275 |
| Total Common Shares Outstanding |